BioArctic AB
Research-oriented Swedish biopharmaceutical company focused on discovery and development of disease‑modifying therapies for neurodegenerative disorders (Alzheimer’s, Parkinson’s, ALS) and treatments for spinal cord injury. Core activities include monoclonal antibody R&D, brain delivery platform development, biomarker and diagnostic development, clinical development across early and late phases, and partnerships/licensing with global pharma. The company has an approved disease‑modifying Alzheimer’s therapy on the market and an active patent strategy.
Industries
Nr. of Employees
medium (51-250)
Patents
Method for treatment of traumatic brain injury targeting aggregated peptides
US-11327080-B2
View DetailsAntibodies and vaccines for use in therapeutic and diagnostic methods for α-synuclein-related disorders
US-9315569-B2
View DetailsProtofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other α-synucleinopathies
US-9084832-B2
View Details
Method for treatment of traumatic brain injury targeting aggregated peptides
US-11327080-B2
View DetailsAntibodies and vaccines for use in therapeutic and diagnostic methods for α-synuclein-related disorders
US-9315569-B2
View DetailsProtofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other α-synucleinopathies
US-9084832-B2
View DetailsProducts
Approved disease‑modifying Alzheimer’s therapy
An approved antibody‑based disease‑modifying therapy for Alzheimer’s disease that is authorized in multiple markets; ongoing development includes new formulations and self‑administered delivery approaches.
Brain delivery platform for antibodies
Platform technology intended to increase antibody concentrations in brain tissue relative to unassisted antibodies; used in internal projects and available for external licensing.
Antibody candidate targeting alpha‑synuclein oligomers
Monoclonal antibody candidate designed to bind and reduce oligomers/protofibrils of alpha‑synuclein for potential disease‑modifying treatment of Parkinson’s disease.
Biodegradable device combined with growth factor for spinal cord repair
Implantable biodegradable device used during neurosurgery in combination with growth factors and/or nerve grafts to promote nerve regeneration after spinal cord injury; progressed into clinical studies and received orphan designation.
BrainTransporter
A proprietary technology platform designed to facilitate the delivery of drugs across the blood-brain barrier.
Leqembi
An antibody targeting oligomers and protofibrils, the harmful forms of Abeta, developed as a disease-modifying treatment against Alzheimer's disease.
Approved disease‑modifying Alzheimer’s therapy
An approved antibody‑based disease‑modifying therapy for Alzheimer’s disease that is authorized in multiple markets; ongoing development includes new formulations and self‑administered delivery approaches.
Brain delivery platform for antibodies
Platform technology intended to increase antibody concentrations in brain tissue relative to unassisted antibodies; used in internal projects and available for external licensing.
Antibody candidate targeting alpha‑synuclein oligomers
Monoclonal antibody candidate designed to bind and reduce oligomers/protofibrils of alpha‑synuclein for potential disease‑modifying treatment of Parkinson’s disease.
Biodegradable device combined with growth factor for spinal cord repair
Implantable biodegradable device used during neurosurgery in combination with growth factors and/or nerve grafts to promote nerve regeneration after spinal cord injury; progressed into clinical studies and received orphan designation.
BrainTransporter
A proprietary technology platform designed to facilitate the delivery of drugs across the blood-brain barrier.
Leqembi
An antibody targeting oligomers and protofibrils, the harmful forms of Abeta, developed as a disease-modifying treatment against Alzheimer's disease.
Expertise Areas
- Therapeutic monoclonal antibody development
- Blood–brain barrier drug delivery
- Biomarker and diagnostic development for neurodegeneration
- Clinical trial management in CNS indications
Key Technologies
- Monoclonal antibody therapeutics
- Carrier-mediated brain delivery (BBB transport platform)
- PET imaging
- Biochemical biomarker assays
News & Updates
Second quarter report for January–June 2026 with accompanying presentation and webcast.
Annual and sustainability report 2025 describing strategy, projects, and financials.
Completion of initial public offering and commencement of trading of B‑shares on Nasdaq Stockholm.
European Patent Office granted a patent covering a monoclonal antibody candidate intended to treat neurodegenerative disorders including Parkinson’s disease.
Positive opinion for orphan drug designation from EMA for a drug candidate intended for traumatic spinal cord injury.
Start of clinical study in Sweden as part of a global Phase II program using an adaptive design to evaluate cognitive and biomarker endpoints in early Alzheimer’s disease.
Second quarter report for January–June 2026 with accompanying presentation and webcast.
Annual and sustainability report 2025 describing strategy, projects, and financials.
Completion of initial public offering and commencement of trading of B‑shares on Nasdaq Stockholm.
European Patent Office granted a patent covering a monoclonal antibody candidate intended to treat neurodegenerative disorders including Parkinson’s disease.
Positive opinion for orphan drug designation from EMA for a drug candidate intended for traumatic spinal cord injury.
Start of clinical study in Sweden as part of a global Phase II program using an adaptive design to evaluate cognitive and biomarker endpoints in early Alzheimer’s disease.